TABLE 1.

Patient and laboratory information for southern California MPXV specimens with the VP37:N267del mutation

Case	Symptom onset date	No. JYNNEOS doses a	Tecovirimat received b ?	Specimen c	Specimen collection date	Specimen source	Reference genome coverage	Mean sequencing depth	GISAID d ID	GenBank ID	SRA e ID
A	2022–11-28	0/2	No	A-1	2022–12-14	Foot	79.79%	4760.8×	EPI_ISL_16997471	OQ503823.2	SRR23580583
B	2022–11-29	0/2	No	B-1	2022–12-02	Unknown	97.51%	557.22×	EPI_ISL_16997450	OQ503816.2	SRR23580591
C	2022–12-01	0/2	No	C-1	2022–12-14	Left upper arm	97.51%	828.74×	EPI_ISL_16997457	OQ503819.2	SRR23580587
D	2022–12-13	0/2	No	D-1	2022–12-19	Right ankle	98.56%	1016.0×	EPI_ISL_16679232	OQ330999.2	SRR23238058
				D-2	2022–12-19	Left wrist	79.41%	2240.4×	EPI_ISL_16679231	OQ330998.2	SRR23238059
				D-3	2022–12-19	Right breast	79.50%	2505.4×	EPI_ISL_16679233	OQ331000.2	SRR23238056
E	2022–12-19	0/2	No	E-1	2023–01-02	Unknown	98.65%	777.32×	EPI_ISL_16930177	OQ547883.2	SRR24451328
F	2023–01-02	2/2	No	F-1	2023–01-08	Unknown	97.63%	3281.2×	EPI_ISL_17211332	OQ644784.2	SRR23893269
G	2023–01-04	0/2	No	G-1	2023–01-06	Unknown	96.85%	409.70×	EPI_ISL_16997466	OQ503826.2	SRR23580580
				G-2	2023–01-06	Left buttock	98.88%	756.89×	EPI_ISL_16930180	OQ547884.2	SRR24451327
H	2023–01-04	1/2	No	H-1	2023–01-10	Unknown	96.16%	624.38×	EPI_ISL_16997441	OQ503830.2	SRR23580575
I	2023–01-06	0/2	No	I-1	2023–01-10	Left buttock	95.39%	345.58×	EPI_ISL_16997402	OQ547899.2	SRR23730906
J	2023–01-08	2/2	No	J-1	2023–01-13	Mouth	99.03%	895.48×	EPI_ISL_17206617	OQ991943.1	SRR24451324
K	2023–01-09	0/2	No	K-1	2023–01-10	Right side face	98.95%	816.41×	EPI_ISL_16930183	OQ547885.2	SRR24451326

^a JYNNEOS doses received 14+ days before symptom onset.

^b Tecovirimat received before specimen collection.

^c All specimens were lesion swabs.

^d GISAID, Global Initiative for Sharing All Influenza Data.

^e SRA, Sequence Read Archive.